I don't think uplisting is what will cut down on t
Post# of 72440
What is going to cut down on the tomfoolery IMO is having a successful Covid drug, money in the bank so new dilution is not necessary, further validation of B via grants and other trials, and most likely some sort of partnership that gives IPIX a great deal of credibility.